Mines D`or Orbec Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 375
- Market Cap
- $121.4M
- Website
- http://www.bluebirdbio.com
- Introduction
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
Phase 1
Completed
- Conditions
- Beta-Thalassemia MajorSickle Cell Disease
- Interventions
- Drug: LentiGlobin BB305 Drug Product
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 7
- Registration Number
- NCT02151526
A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease
Phase 1
Completed
- Conditions
- Sickle Cell Disease
- Interventions
- Genetic: lovo-cel
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 54
- Registration Number
- NCT02140554
A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
Phase 2
Completed
- Conditions
- Cerebral Adrenoleukodystrophy (CALD)
- Interventions
- Genetic: Lenti-D Drug Product (eli-cel)
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 32
- Registration Number
- NCT01896102
- Locations
- 🇺🇸
Mattel Children's Hospital UCLA/Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇦🇷Medeos SRL, Buenos Aires, Argentina
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
Phase 1
Completed
- Conditions
- β-thalassemia Major
- Interventions
- Genetic: LentiGlobin BB305 Drug Product
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- bluebird bio
- Target Recruit Count
- 19
- Registration Number
- NCT01745120
© Copyright 2025. All Rights Reserved by MedPath